###### Key questions

What is already known about this subject?
=========================================

-   For the prevention of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF), clinical guidelines recommend treatment with non-vitamin K oral anticoagulants (NOACs) rather than warfarin. However, the effectiveness and safety of NOACs in Japanese clinical practice remain to be fully elucidated, particularly in patients with high-risk profiles compared with those enrolled in clinical trials.

What does this study add?
=========================

-   This study found that the majority of patients with NVAF treated in Japanese clinical practice received reduced doses of NOACs---a treatment pattern likely underpinned by bleeding-related concerns. Despite the dose reduction, the risks of stroke/SE, major bleeding and major intracranial haemorrhage were significantly lower for NOACs versus warfarin in Japanese patients with NVAF.

How might this impact on clinical practice?
===========================================

-   These findings provide important real-world evidence describing treatment patterns and clinical outcomes for elderly patients with NVAF treated in Japanese clinical practice. They indicate that NOAC treatment was associated with clinical benefits versus warfarin, even in a population primarily treated with reduced doses.

Introduction {#s1}
============

Atrial fibrillation (AF) is the most common arrhythmia and is observed in \<1% of the total population in Japan.[@R1] The prevalence of AF increases with age, rising to approximately 14% in patients aged \>80 years.[@R1] AF is a well-established risk factor for stroke, systemic embolism (SE) and death.[@R3] Recent guidelines recommend treatment with non-vitamin K oral anticoagulants (NOACs) (ie, apixaban, dabigatran, edoxaban and rivaroxaban) for eligible oral anticoagulant (OAC)-naïve patients with non-valvular atrial fibrillation (NVAF).[@R2] Multiple randomised controlled trials (RCTs) have supported the benefits of NOACs versus warfarin in patients with NVAF,[@R6] with a meta-analysis confirming that NOACs significantly lower the risk of stroke/SE with a risk of major bleeding similar to that associated with warfarin.[@R10]

While RCTs are the gold standard for demonstrating the effectiveness of interventions, they are not fully representative of an unselected real-world population, thereby limiting the relevance of their findings to clinical practice. Consequently, a number of observational, real-world evidence studies have emerged to provide supportive evidence of the safety and/or effectiveness of NOACs in clinical practice.[@R11] However, there remain several unmet knowledge gaps in the literature regarding the clinical outcomes of NOAC treatment in patients with NVAF, particularly in patient subgroups at high risk of adverse outcomes.[@R19]

All four NOACs (apixaban, dabigatran, edoxaban and rivaroxaban) have been approved in Japan for the prevention of stroke and SE in patients with NVAF.[@R21] Importantly, dosing of NOACs in Japan differs slightly from that in other countries given the higher bleeding complication rates reported in East Asian patients; for example, the approved dose of rivaroxaban is 10/15 mg daily in Japan.[@R21] Given the unique setting surrounding the use of NOACs, and considering they are often initiated at reduced doses, the impact of NOACs on safety (ie, the risk of bleeding) and effectiveness (ie, the risk of stroke or SE) outcomes in Japanese patients with NVAF requires further elucidation.

Methods {#s2}
=======

Study design {#s2-1}
------------

This was a non-interventional, retrospective, observational study conducted from March 2011 (ie, when the first NOAC, dabigatran, was approved in Japan) to July 2018 to evaluate the safety and effectiveness of apixaban, dabigatran, edoxaban and rivaroxaban, each separately, versus warfarin in Japanese patients with NVAF. Written consent from study participants was not necessary in a retrospective study using an existing structured database according to the Japanese Ethical Guidelines. All data were anonymised, and any information that could be used to identify individuals or hospitals was removed.

We used deidentified health claims data from 372 acute care hospitals across Japan available from the Medical Data Vision Co Ltd (MDV; Tokyo, Japan) database.[@R22] In brief, the MDV database comprises administrative data for approximately 24 million individuals in the inpatient and outpatient settings.[@R22] Each patient is assigned a specific ID to which all inpatient and outpatient data are linked. The distribution of demographic characteristics, including age and sex, of patients registered in the MDV database is very similar to the national population statistics in Japan. For each prescription recorded in the MDV database, the diagnosis is listed according to 10th Revision of the International Classification of Diseases (ICD-10) codes or local disease codes.

Patients registered in the MDV database between 1 March 2011 and 31 July 2018 were selected based on the following inclusion criteria: diagnosis of AF at any time during the preindex period and first prescription of any OAC (apixaban, dabigatran, edoxaban, rivaroxaban or warfarin) after a diagnosis of AF; age 18 years or older on the index date (defined as the date of the first prescription of any OAC); and no OAC prescription during the year preceding the index date (baseline period). The first OAC prescription recorded in the database was used to identify the patient's index date, treatment cohort and OAC dose. Patients with a diagnosis of valvular AF, postoperative AF, AF associated with mechanical valve malfunction, AF associated with mechanical complication of heart valve prosthesis or rheumatic AF during the baseline period were excluded. Additionally, patients with a diagnosis of hyperthyroidism or thyrotoxicosis, those who underwent procedures involving prosthetic heart valves performed during the baseline period and those with haemodialysis or pregnancy during the baseline period were also excluded.

Patients were followed from the index date until any of the following events, whichever occurred first: discontinuation of the index OAC, defined as a continuous gap of 45 days or more between the expected refill date and the actual refill date; switch to another OAC---if the index OAC was discontinued and another OAC was started within 45 days of the prescription refill date of the index OAC; lack of further records in the database---if no further relevant records were added (eg, no further refills or visits), the last date of the patient's record in the database was used; occurrence of stroke, SE or haemorrhagic adverse events; or an elapse of 2 years from the index date.

Endpoints {#s2-2}
---------

Individual NOACs and warfarin were compared with respect to the incidence of stroke/SE and bleeding in cohorts after inverse probability of treatment weighting with stabilised weights (s-IPTW) was applied. The safety endpoints were major bleeding and any bleeding, defined as bleeding requiring hospitalisation (major bleeding) and any bleeding event recorded after the index date regardless of severity or need for hospitalisation (any bleeding). Bleeding sites were not considered in the primary analysis. The effectiveness primary endpoint was a composite of stroke and SE requiring hospitalisation. Stroke was defined as ischaemic or haemorrhagic stroke. Haemorrhagic stroke was included both as a safety endpoint and as an effectiveness endpoint. For the secondary analyses, major gastrointestinal (GI) bleeding, any GI bleeding, major intracranial haemorrhage (ICH) and any ICH were the safety-related secondary endpoints. Ischaemic stroke, haemorrhagic stroke and SE were the effectiveness-related secondary endpoints. The primary safety and effectiveness endpoints were also assessed in the following prespecified subgroups: age (≥75 years/\<75 years or ≥80 years/\<80 years), body weight (≥60 kg/\<60 kg), renal disease (yes/no), concomitant use of antiplatelet drugs (yes/no) and NOAC dose (standard/reduced). Similar to the primary analyses, s-IPTW was applied to balance patient characteristics among these subgroups. The ICD-10 codes and disease codes used in the study are listed in [online supplementary tables 1 and 2](#SP1){ref-type="supplementary-material"}.
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Statistics {#s2-3}
----------

All analyses were conducted with SAS V.9.4. A propensity score was calculated based on multinomial logistic regression in order to account for confounding effects and to ensure that patient characteristics were balanced between the NOAC and warfarin cohorts. An IPTW method using the calculated propensity score was applied, and to avoid sample size inflation and ensure appropriate estimation of variances, s-IPTW was used.[@R23] Weight truncation was not conducted. The following clinical and demographic characteristics, collected during the baseline period or at the index date, were included as covariates to calculate the propensity score: sex and age, comorbidities (ie, heart failure, coronary heart disease, peripheral vascular disorder, myocardial infarction, stroke, transient ischaemic attack, SE, renal dysfunction, hepatic dysfunction, bleeding history, hypertension and diabetes mellitus), concomitant medications (ie, antiplatelet drugs, nonsteroidal anti-inflammatory drugs, gastric secretion inhibitors, statins, heparins and antihypertensive drugs) and presence of cardioversion and ablation procedures. CHADS~2~ and CHA~2~DS~2~-VASc scores were calculated using these clinical and demographic characteristics.[@R25] The calculated s-IPTW was simultaneously applied to the five crude OAC cohorts to obtain four paired NOAC/warfarin cohorts, wherein demographic and clinical characteristics of each OAC cohort were balanced. The covariate balance between the NOAC/warfarin cohorts after s-IPTW was assessed with respect to standardised differences using a threshold of 0.1; previous studies have suggested that a standardised difference of \>0.1 may indicate the presence of a meaningful imbalance of covariates between paired treatments.[@R27] The 2-year cumulative incidence rates of major bleeding, any bleeding and stroke/SE in the cohorts after s-IPTW were plotted with Kaplan-Meier curves. HRs with 95% CIs were calculated using a Cox proportional hazards regression model that incorporated only the index OACs as independent variables.

Sensitivity analyses {#s2-4}
--------------------

Two sensitivity analyses were conducted. First, a sensitivity analysis was performed by restricting the follow-up period to 1 year, and differences in the results versus the 2-year follow-up period were compared. Second, a conventional 1:1 propensity score matching method was used to assess the robustness of the method used for addressing the covariate imbalance between cohorts. As in the main analysis, a threshold of 0.1 was used for confirming covariate balance between the two groups, and HRs with 95% CIs were calculated using a Cox proportional hazards model.

Results {#s3}
=======

Baseline characteristics in the crude cohorts before s-IPTW {#s3-1}
-----------------------------------------------------------

Overall, 73 989 patients were eligible for the analysis after applying the selection criteria ([figure 1](#F1){ref-type="fig"}). Patients were divided into five cohorts: 15 902 patients initiated warfarin; 22 336 patients initiated apixaban 2.5 mg or 5 mg twice daily; 6925 patients initiated dabigatran 110 mg or 150 mg twice daily; 12 262 patients initiated edoxaban 30 mg or 60 mg once daily; and 16 564 patients initiated rivaroxaban 10 mg or 15 mg once daily ([figure 1](#F1){ref-type="fig"}). Baseline characteristics in the crude cohorts before s-IPTW are reported in [online supplementary table S3](#SP1){ref-type="supplementary-material"}. The mean (SD) duration of treatment ranged from 265 (263.8) to 868 (725) days. Apixaban was the most frequently prescribed NOAC, and 47.2%--76.2% of patients were initiated on reduced doses of NOACs. The warfarin cohort contained the oldest patients, with the highest mean CHADS~2~ and CHA~2~DS~2~-VASc scores and the most comorbidities, and patients in the apixaban cohort tended to be older with higher mean risk scores ([online supplementary table S3](#SP1){ref-type="supplementary-material"}).

![Flow chart of patient allocation to each OAC cohort. AF, atrial fibrillation; MDV, Medical Data Vision Co Ltd; OAC, oral anticoagulant.](openhrt-2019-001232f01){#F1}

Incidence of bleeding and stroke/SE in the crude cohorts before s-IPTW {#s3-2}
----------------------------------------------------------------------

Between-cohort differences in event rates (per 100 person-years) reflected differences in baseline patient risk characteristics ([online supplementary table S3](#SP1){ref-type="supplementary-material"}). The event rates of major bleeding, any bleeding and stroke/SE were highest in the warfarin cohort; the event rates of major bleeding and any bleeding were lowest in the dabigatran cohort, and the event rate of stroke/SE was lowest in the rivaroxaban cohort ([online supplementary table S4](#SP1){ref-type="supplementary-material"}).

Patient characteristics in the cohorts after s-IPTW {#s3-3}
---------------------------------------------------

The standardised differences between the s-IPTW-balanced cohorts in patient characteristics used for calculating the propensity score were \<0.1, suggesting that patient characteristics were well balanced between the cohorts ([table 1](#T1){ref-type="table"}). For patients treated with dabigatran, the age, CHADS~2~ and CHA~2~DS~2~-VASc scores and proportion of patients with comorbidities were slightly higher than those in the crude cohort. The proportion of patients treated with reduced doses of NOACs remained high (52.8%--81.9%; [table 1](#T1){ref-type="table"}).

###### 

Demographics and clinical characteristics of patients with 365-day baseline after s-IPTW

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                   Warfarin\       Apixaban\               Dabigatran\               Edoxaban\              Rivaroxaban\                                                   
                                              n=19 059        5/2.5 mg twice daily\   150/110 mg twice daily\   60/30 mg once daily\   15/10 mg once daily\                                           
                                                              n=22 752                n=8003                    n=12 592               n=17 481                                                       
  ------------------------------------------- --------------- ----------------------- ------------------------- ---------------------- ---------------------- ------------- --------- --------------- ---------
  Sex category (male)†                        11 656 (61.2)   13 912 (61.2)           −0.0002                   4963 (62.0)            0.0176                 7691 (61.1)   −0.0018   10 672 (61.1)   −0.0022

  Age, years                                                                                                                                                                                          

   Mean±SD†                                   76.1±11.9       76.1±10.8               −0.0016                   75.6±10.3              −0.0464                76.2±10.8     0.0048    76.2±10.6       0.0074

   \<65                                       2542 (13.3)     2829 (12.4)             −0.0270                   954 (11.9)             −0.0428                1586 (12.6)   −0.0222   2119 (12.1)     −0.0365

   65--74                                     4707 (24.7)     5984 (26.3)             0.0368                    2330 (29.1)            0.0996                 3249 (25.8)   0.0254    4679 (26.8)     0.0473

   ≥75                                        11 809 (62.0)   13 939 (61.3)           −0.0144                   4719 (59.0)            −0.0612                7757 (61.6)   −0.0074   10 683 (61.1)   −0.0175

  BMI, kg/m^2^                                                                                                                                                                                        

   \<18                                       1170 (6.1)      1048 (4.6)              −0.0679                   286 (3.6)              −0.1193                614 (4.9)     −0.0553   878 (5.0)       −0.0486

   18 to \<22                                 3925 (20.6)     3555 (15.6)             −0.1293                   1123 (14.0)            −0.1741                1858 (14.8)   −0.1536   2587 (14.8)     −0.1524

   22 to \<25                                 3541 (18.6)     3123 (13.7)             −0.1322                   1185 (14.8)            −0.1012                1572 (12.5)   −0.1690   2356 (13.5)     −0.1394

   ≥25                                        3193 (16.8)     2671 (11.7)             −0.1438                   1024 (12.8)            −0.1117                1320 (10.5)   −0.1837   2181 (12.5)     −0.1213

   Missing                                    7230 (37.9)     12 354 (54.3)           0.3328                    4384 (54.8)            0.3428                 7229 (57.4)   0.3975    9479 (54.2)     0.3313

  Dose group                                                                                                                                                                                          

   Reduced                                    --              12 539 (55.1)           NA                        6557 (81.9)            NA                     9376 (74.5)   N/A       9221 (52.8)     N/A

   Standard                                   --              10 213 (44.9)           NA                        1445 (18.1)            NA                     3216 (25.5)   N/A       8260 (47.3)     N/A

  CHADS~2~                                                                                                                                                                                            

   Mean±SD                                    2.3±1.6         2.3±1.5                 −0.0216                   2.2±1.6                −0.0466                2.3±1.6       −0.0176   2.3±1.5         −0.0211

   0                                          2003 (10.5)     2914 (12.8)             0.0715                    1007 (12.6)            0.0650                 1648 (13.1)   0.0800    2107 (12.1)     0.0487

   1                                          4517 (23.7)     5246 (23.1)             −0.0152                   1861 (23.3)            −0.0105                2889 (22.9)   −0.0180   4089 (23.4)     −0.0073

   2                                          4511 (23.7)     4863 (21.4)             −0.0550                   1858 (23.2)            −0.0106                2669 (21.2)   −0.0594   3881 (22.2)     −0.0349

   ≥3                                         8028 (42.1)     9730 (42.8)             0.0130                    3276 (40.9)            −0.0240                5387 (42.8)   0.0133    7404 (42.4)     0.0047

  CHA~2~DS~2~-VASc                                                                                                                                                                                    

   Mean±SD                                    3.8±2.1         3.8±1.9                 −0.0146                   3.8±2.0                −0.0346                3.8±2.0       −0.0124   3.8±1.9         −0.0127

   0                                          574 (3.0)       783 (3.4)               0.0241                    236 (3.0)              −0.0037                455 (3.6)     0.0335    520 (3.0)       −0.0023

   1                                          1408 (7.4)      1732 (7.6)              0.0085                    656 (8.2)              0.0302                 1017 (8.1)    0.0259    1328 (7.6)      0.0079

   2                                          2783 (14.6)     3578 (15.7)             0.0312                    1239 (15.5)            0.0246                 1965 (15.6)   0.0280    2732 (15.6)     0.0286

   ≥3                                         14 293 (75.0)   16 660 (73.2)           −0.0404                   5871 (73.4)            −0.0372                9155 (72.7)   −0.0522   12 901 (73.8)   −0.0273

  PT-INR‡ (mean±SD)                           1.60±0.74       --                      --                        --                     --                     --            --        --              --

  Heart failure†                              7156 (37.5)     8442 (37.1)             −0.0091                   2944 (36.8)            −0.0158                4679 (37.2)   −0.0080   6480 (37.1)     −0.0098

  Coronary heart disease†                     4873 (25.6)     5808 (25.5)             −0.0009                   2041 (25.5)            −0.0015                3198 (25.4)   −0.0040   4407 (25.2)     −0.0082

  Peripheral arterial disorder†               1447 (7.6)      1710 (7.5)              −0.0028                   606 (7.6)              −0.0007                940 (7.5)     −0.0047   1312 (7.5)      −0.0033

  Myocardial infarction†                      570 (3.0)       676 (3.0)               −0.0013                   238 (3.0)              −0.0013                370 (2.9)     −0.0033   516 (3.0)       −0.0024

  Hyperthyroidism or thyrotoxicosis           434 (2.3)       477 (2.1)               −0.0121                   172 (2.1)              −0.0089                264 (2.1)     −0.0120   362 (2.1)       −0.0139

  Stroke, TIA or SE†                          4086 (21.4)     4756 (20.9)             −0.0131                   1624 (20.3)            −0.0280                2641 (21.0)   −0.0113   3696 (21.2)     −0.0071

  Renal dysfunction†                          1326 (7.0)      1554 (6.8)              −0.0051                   560 (7.0)              0.0014                 864 (6.9)     −0.0039   1224 (7.0)      0.0017

  Liver dysfunction†                          2454 (12.9)     2857 (12.6)             −0.0096                   1034 (12.9)            0.0013                 1583 (12.6)   −0.0092   2184 (12.5)     −0.0116

  Bleeding diagnosis†                         2322 (12.2)     2754 (12.1)             −0.0025                   1002 (12.5)            0.0101                 1530 (12.2)   −0.0011   2136 (12.2)     0.0010

  Hypertension†                               10 650 (55.9)   12 527 (55.1)           −0.0165                   4377 (54.7)            −0.0238                6945 (55.2)   −0.0147   9602 (54.9)     −0.0191

  Diabetes mellitus†                          5791 (30.4)     6833 (30.0)             −0.0077                   2414 (30.2)            −0.0049                3778 (30.0)   −0.0085   5236 (30.0)     −0.0095

  Cancer                                      4201 (22.0)     5252 (23.1)             0.0249                    1872 (23.4)            0.0323                 2969 (23.6)   0.0367    3925 (22.5)     0.0099

  Treated with antiplatelet drugs†            4459 (23.4)     5181 (22.8)             −0.0149                   1781 (22.3)            −0.0272                2870 (22.8)   −0.0145   3960 (22.7)     −0.0177

  Treated with NSAIDs†                        5947 (31.2)     6993 (30.7)             −0.0102                   2474 (30.9)            −0.0062                3894 (30.9)   −0.0061   5401 (30.9)     −0.0067

  Treated with gastric secretion inhibitor†   7736 (40.6)     9113 (40.1)             −0.0110                   3180 (39.7)            −0.0175                5045 (40.1)   −0.0108   7022 (40.2)     −0.0086

  Treated with statin-based drug†             2677 (14.0)     3200 (14.1)             0.0006                    1084 (13.5)            −0.0146                1765 (14.0)   −0.0008   2410 (13.8)     −0.0074

  Treated with antiarrhythmics                8481 (44.5)     9968 (43.8)             −0.0138                   3512 (43.9)            −0.0125                5529 (43.9)   −0.0120   7677 (43.9)     −0.0117

  Treated with beta-blockers                  3972 (20.8)     4651 (20.4)             −0.0099                   1613 (20.2)            −0.0169                2569 (20.4)   −0.0110   3526 (20.2)     −0.0167

  Treated with heparin†                       3905 (20.5)     4552 (20.0)             −0.0121                   1625 (20.3)            −0.0048                2520 (20.0)   −0.0119   3555 (20.3)     −0.0039

  Cardioversion†                              142 (0.7)       162 (0.7)               −0.0038                   67 (0.8)               0.0101                 91 (0.7)      −0.0030   122 (0.7)       −0.0052

  Therapy days (mean±SD)                      451.5±632.9     395.9±412.1             −0.1041                   823.4±765.1            0.5296                 263.0±266.7   −0.3882   415.4±471.2     −0.0647
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Calculated when compared with the warfarin cohort.

†Variables included in the calculation of propensity score.

‡The Japanese treatment guidelines recommend target INR ranges of 2.0--3.0 for patients aged less than 70 years and 1.6--2.6 for patients aged 70 years or older.

BMI, body mass index; NSAID, non-steroidal anti-inflammatory drug; PT-INR, prothrombin time--international normalised ratio; SE, systemic embolism; s-IPTW, inverse probability of treatment weighting with stabilised weights; TIA, transient ischaemic attack.

Bleeding and stroke/SE risk in the cohorts after s-IPTW {#s3-4}
-------------------------------------------------------

Unweighted Kaplan-Meier cumulative incidence plots of any bleeding, major bleeding and stroke/SE events are presented in [figure 2](#F2){ref-type="fig"}. Compared with warfarin, all NOACs were associated with a significantly lower risk of stroke/SE and major bleeding ([figure 3](#F3){ref-type="fig"}). Apixaban was associated with a significantly lower risk of any bleeding, and dabigatran and rivaroxaban had HRs below 1; however, statistical significance was not achieved ([figure 3](#F3){ref-type="fig"}).

![Kaplan-Meier curves for incidence of (A) any bleeding, (B) major bleeding and (C) stroke/SE. SE, systemic embolism.](openhrt-2019-001232f02){#F2}

![Forest plot depicting the risk of events for NOACs versus warfarin. HRs and 95% CIs are given for each NOAC. NOAC, non-vitamin K oral anticoagulant; SE, systemic embolism.](openhrt-2019-001232f03){#F3}

Secondary safety and effectiveness endpoints {#s3-5}
--------------------------------------------

A significantly lower risk of major ICH was observed for all NOACs versus warfarin, and dabigatran and rivaroxaban were associated with a significantly lower risk of any ICH ([table 2](#T2){ref-type="table"}). Apixaban was associated with a significantly lower risk of major GI bleeding, and apixaban and rivaroxaban were associated with a significantly lower risk of any GI bleeding ([table 2](#T2){ref-type="table"}). Compared with warfarin, all of apixaban, edoxaban and rivaroxaban were associated with a significantly lower risk of ischaemic stroke, while dabigatran and rivaroxaban were associated with a significantly lower risk of haemorrhagic stroke. All NOACs had HRs below 1 for SE; however, statistical significance was not achieved ([table 2](#T2){ref-type="table"}).

###### 

HRs with 95% CIs for secondary endpoints

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                   N (NOAC/warfarin)   Apixaban\                            Dabigatran 150/110 mg twice daily over warfarin   Edoxaban\                           Rivaroxaban 15/10 mg once daily over warfarin
                                                       5/2.5 mg twice daily over warfarin                                                     60/30 mg once daily over warfarin   
  -------------------------------- ------------------- ------------------------------------ ------------------------------------------------- ----------------------------------- -----------------------------------------------
  Ischaemic stroke                 HR                  0.63                                 0.90                                              0.74                                0.74

  95% CI                           (0.524 to 0.759)    (0.716 to 1.140)                     (0.586 to 0.925)                                  (0.607 to 0.909)                    

  P value                          \<0.0001            0.3906                               0.0087                                            0.0039                              

  Haemorrhagic stroke              HR                  0.75                                 0.41                                              0.73                                0.63

  95% CI                           (0.545 to 1.029)    (0.244 to 0.703)                     (0.479 to 1.102)                                  (0.432 to 0.922)                    

  P value                          0.0743              0.0011                               0.1332                                            0.0175                              

  Systemic embolism                HR                  0.48                                 0.97                                              0.46                                0.50

  95% CI                           (0.198 to 1.165)    (0.316 to 2.959)                     (0.145 to 1.487)                                  (0.183 to 1.349)                    

  P value                          0.1050              0.9519                               0.1966                                            0.1701                              

  Major GI bleeding                HR                  0.76                                 0.92                                              0.83                                0.92

  95% CI                           (0.579 to 0.987)    (0.655 to 1.286)                     (0.602 to 1.158)                                  (0.693 to 1.213)                    

  P value                          0.0394              0.6175                               0.2798                                            0.5425                              

  Any GI bleeding                  HR                  0.87                                 1.04                                              0.99                                0.87

  95% CI                           (0.779 to 0.970)    (0.901 to 1.203)                     (0.871 to 1.125)                                  (0.768 to 0.976)                    

  P value                          0.0121              0.5870                               0.8812                                            0.0186                              

  Major intracranial haemorrhage   HR                  0.58                                 0.42                                              0.60                                0.52

  95% CI                           (0.452 to 0.757)    (0.283 to 0.637)                     (0.427 to 0.836)                                  (0.379 to 0.702)                    

  P value                          \<0.0001            \<0.0001                             0.0026                                            \<0.0001                            

  Any intracranial haemorrhage     HR                  0.89                                 0.79                                              0.92                                0.81

  95% CI                           (0.781 to 1.010)    (0.658 to 0.946)                     (0.789 to 1.076)                                  (0.701 to 0.936)                    

  P value                          0.0715              0.0104                               0.3014                                            0.0044                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GI, gastrointestinal; NOAC, non-vitamin K oral anticoagulant.

Subgroup analyses in patients with high-risk profiles {#s3-6}
-----------------------------------------------------

[Online supplementary table S5](#SP1){ref-type="supplementary-material"} reports the results of the subgroup analysis in high-risk patients. Across age categories, the majority of the HRs for major bleeding, any bleeding and stroke/SE were equal to or below 1 for all NOACs versus warfarin, although not all were statistically significant. In the very elderly age group (≥80 years), apixaban, edoxaban and rivaroxaban were associated with a significantly lower risk of major bleeding and stroke/SE ([online supplementary table S5](#SP1){ref-type="supplementary-material"}).

In patients with body weight \<60 kg, apixaban was associated with a significantly lower risk of stroke/SE, and there was a trend towards risk reduction for major bleeding and any bleeding with NOACs versus warfarin in patients with body weight ≥60 kg. In patients with renal disease, the HRs for apixaban alone (vs warfarin) were below 1 for major bleeding, any bleeding and stroke/SE, with statistical significance observed for the risk reduction in stroke/SE versus warfarin ([online supplementary table S5](#SP1){ref-type="supplementary-material"}).

When stratified by initial dose (ie, standard vs reduced), the risk of any bleeding was significantly higher with the standard dose of edoxaban, and the risk of stroke/SE was significantly lower with a reduced dose of apixaban versus warfarin ([online supplementary table S5](#SP1){ref-type="supplementary-material"}).

Sensitivity analysis {#s3-7}
--------------------

There were no large differences in HRs between the two different observational periods (1 year and 2 years), although statistical significance was not always obtained for the HRs in the 1-year observation period owing to the small number of events ([online supplementary table S6](#SP1){ref-type="supplementary-material"}). Results of the second sensitivity analysis were also largely consistent with the main results ([online supplementary table S7](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

In this large, real-world, observational study, we evaluated the effectiveness and safety of four NOACs currently approved for stroke/SE prevention versus warfarin in Japanese patients with NVAF. The primary results indicated that all NOACs were associated with a significantly lower risk of major bleeding and stroke/SE compared with warfarin. Notable results from the secondary analyses were a significantly lower risk of major ICH for all NOACs, and reductions in the risk of any and major GI bleeding with apixaban, versus warfarin. Broadly, these real-world results provide supportive evidence for the existing RCTs that have demonstrated the clinical benefits of NOACs versus warfarin in patients with NVAF.[@R6] Moreover, the current study builds on the emerging, real-world evidence base for the effectiveness and safety of NOACs in Japanese clinical practice.[@R15]

Reduced dosing of NOACs is a pertinent clinical concern as it may impact the safety and/or effectiveness of treatment.[@R18] In the current study, risks for bleeding and stroke/SE were generally consistent between the standard-dose and reduced-dose NOAC subgroups, and we observed a significantly lower risk of stroke/SE with reduced-dose apixaban versus warfarin. Thus, the current results differ from recent real-world study results, in which reduced-dose NOAC treatment was associated with increased rates of thromboembolic and major haemorrhagic events, along with stroke/SE and myocardial infarction, in Japanese patients with NVAF.[@R18] Of note, the proportions of patients initiated on reduced doses of NOACs were higher than those reported in studies conducted in the USA,[@R33] Korea and Taiwan[@R36] and in real-world studies in Japan.[@R17] It is likely that the high rates of dose reduction observed in the current study were primarily attributable to the risk characteristics of the patient sample. For instance, in a recent cross-sectional analysis of a multicentre outpatient registry in Japan, the independent predictors of NOAC underdosing in newly diagnosed patients with NVAF were older age, concomitant antiplatelet therapy, impaired renal function and prior heart failure or left ventricular dysfunction.[@R40]

Appropriate use of NOACs in patients with NVAF and comorbid renal disease remains the subject of ongoing investigation,[@R41] and worsening of renal function in patients with AF is independently associated with ischaemic stroke and haemorrhage.[@R43] NOAC-specific differences in renal excretion rates have been observed,[@R44] with dabigatran and edoxaban having the greatest dependence on renal elimination compared with apixaban and rivaroxaban.[@R45] A recent meta-analysis of RCTs and observational studies in patients with renal disease reported that NOACs significantly lowered the risk of ICH, stroke/SE and major bleeding versus warfarin.[@R42] In the current study, apixaban was the only NOAC with a significantly lower risk of stroke/SE, whereas the risk of stroke/SE was significantly higher for rivaroxaban versus warfarin in patients with NVAF and comorbid renal disease. However, owing to the relatively small number of patients with renal disease, along with the observational design of the study, firm conclusions regarding the safety and effectiveness of NOACs in Japanese patients with NVAF and comorbid renal disease should not be made on the basis of these results.

Strengths of the current study's design and results include the MDV database being representative of the Japanese population, the high mean age of the patients (ie, most were very elderly), the large sample size and the inclusion of all four approved NOACs in the analyses. Additionally, a majority of the patients were treated with reduced doses of NOACs, which allowed for the evaluation of effectiveness and safety in patients on reduced doses; however, this also places limitations on the generalisability of the results to patients with NVAF primarily treated with standard doses of NOACs. Furthermore, the study provides much-needed data on the effectiveness and safety of NOACs in Japanese patients with NVAF, as many studies have been conducted in Western populations. However, the study has several limitations. First, data were obtained from a claims database containing information provided by hospitals applying the flat-fee payment system, which are mostly large hospitals responsible for acute care. Therefore, a significant proportion of the patients included were likely in poorer health than the average population requiring hospitalisation, possibly having more comorbidities and a higher risk of stroke/SE and bleeding. Second, the claims data did not include vital signs or laboratory measurements (eg, blood pressure, international normalised ratio values, renal function parameters), which precluded calculation of a HAS-BLED score.[@R46] Therefore, we were unable to consider these variables in the calculation of the propensity score, and consequently, there is no guarantee that these characteristics were fully balanced after s-IPTW. Thus, the influence of unexamined confounding factors cannot be fully excluded. Third, we could not provide an estimate of follow-up loss as we had no subsequent data on patients who had visited a different hospital or clinic after being registered with one of the hospitals contributing to the MDV database. This could have led to an underestimation of the incidence of stroke/SE or major bleeding events. Fourth, results of some subgroup analyses are not conclusive owing to the smaller number of patients and lower statistical power. Fifth, primary endpoints were defined as resulting in hospitalisation, which differs from the adjudicated endpoints typically used in RCTs, and we did not include a mortality endpoint. Finally, while the majority of patients received reduced doses of NOACs, we were unable to determine whether this level of dosing was appropriate or if off-label underdosing of NOACs had any impact on the clinical outcomes owing to the unavailability of clinical information in the MDV database.

In conclusion, a large proportion of patients with NVAF initiated treatment with reduced-dose NOACs in contemporary Japanese practice. Despite this, the risks of stroke/SE, along with major bleeding, were significantly lower for NOACs versus warfarin. The results were largely consistent across the patient subgroups with higher risk profiles, such as those with older age, lower body weight and renal disease.
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